Skip to main content
. Author manuscript; available in PMC: 2016 Jun 7.
Published in final edited form as: Allergy. 2014 Apr 17;69(6):810–813. doi: 10.1111/all.12409

Fig. 2. KIT D816V allele burden during the follow-up.

Fig. 2

Change in KIT D816V mutation positive allele fraction during the follow-up in patients without (A; N=19) and with cytoreductive treatment (B; N=11). The allele burden was normalized to the mutant burden at diagnosis. The value of 1 corresponds to no change in allele fraction over time and the values of 0.1 and 10 (dotted lines) correspond to 10 fold decreases and increases. (C-F) Follow-up of KIT D816V allele burden (blue) and serum tryptase (black) in individual mastocytosis patients with an uneventful course (C, ISM; D, SSM), a patient initially diagnosed as ISM with disease progression to ASM-CMML and response to cytoreductive therapy with cladribine (2-CDA) (E), and a patient with SSM receiving cytoreductive therapy due to recurrent episodes of life threatening vascular instability requiring epinephrine support (F).